Member Info for Krone

Clearly not Sierra's prime focus....to me Nick Glover sounds luke warm....compared to his obvious enthusiasm for Momelotinib

And looks like huge potential for application in numerous other conditions http://po.st/SzssYW

http://filecache.investorroom.com/mr5ircnw_sierra/255/ASCO%202019%20SRA737-02_Poster_final.pdf

http://filecache.investorroom.com/mr5ircnw_sierra/256/ASCO%202019%20SRA737-01%20Poster_final2.pdf

Thoth2, Excellent, many thanks...

Thoth2, what’s the potential market size in anogenital?

“We will further analyze these opportunities and evaluate next steps with this asset over the coming months, exploring options to enable the continued advancement of SRA737 in the context of our emerging pipeline." Code for, actually we are focussed on momelotinib and will licence/sell SRA737???

- Anti-cancer activity demonstrated across multiple indications and genetic contexts....

Given his world class credentials the fact that Professor Johann De Bono is presenting on Monday must carry very significant weight in that he would be unlikely to ally himself, at a high profile event, to a project which isn't progressing well.
'In 2015, he was named among the “World’s Most Influential Scientific Minds”, and in July 2016 was named as Regius Professor of Cancer Research – a rare award bestowed by the Sovereign by Royal Warrant to recognise exceptionally high-quality research at an institution, and the first such Professorship devoted to cancer.'

Sierra Oncology to Present Momelotinib and SRA737 Overview at the Jefferies Global Healthcare Conference in New York - Presentation scheduled for 8:00 am ET on June 5, 2019 - VANCOUVER, May 28, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company and updates concerning its clinical stage drug candidates, momelotinib and SRA737, at 8:00 am ET on Wednesday, June 5 at the Jefferies Global Healthcare Conference being held in New York. During the presentation, Dr. Glover will discuss: updated progress in the development program for momelotinib, the company's Phase 3 JAK1, JAK2 and ACVR1 inhibitor for the treatment of myelofibrosis. preliminary clinical efficacy data for Sierra's Chk1 inhibitor, SRA737, which will have been presented on June 1st at the 2019 ASCO Annual Meeting. A live audio webcast and archive of the presentation will be accessible through the Sierra Oncology website at www.sierraoncology.com.

Sareum Holdings plc and Stephen Parker followed DynastyBio http://www.dynastybio.com/
Does this indicate that we are looking East for a deal and should we be encouraged or concerned, particularly after the HMUBEC episode??

Checkpoint inhibitors are the big money-makers
Checkpoint inhibitors are a particular type of monoclonal antibodies that help to flag up cancer cells to the immune system.
Cancer Research has a particularly good analogy: cancer can sometimes push a stop button on the immune cells, so the immune system won’t attack them. Checkpoint inhibitors block cancers from pushing this stop button.
Merck’s Keytruda is probably the most well-known monoclonal antibody. It is what’s known as a PD-1 inhibitor, and sales of the drug doubled last year to over US$7bn.
Peak sales could be as high as US$16bn, according to some analysts, as it takes a stranglehold on the massive lung cancer market.
Bristol-Myers Squibb’s rival PD-1 inhibitor, called Opdivo, used to be the biggest, but it was overtaken by Keytruda last summer. Still, at just shy of US$7bn, it wasn’t too far behind.

So we are expecting preliminary SRA737 data from Sierra on 1st June. BIO International 3-6 June would provide a high profile opportunity for an announcement re SDC1801/1802 - promises to be an interesting couple of weeks....

Nuevolution read across?

Small biotech, similar pipeline in terms of number of assets, similar stages of development, similar sized BOD, £20m vs potential $2.2b......tick bloody tock.....

Merck bets $2.2B on a small cancer drug biotech, snatching it out of the IPO lineup.

Merck R&D chief Roger Perlmutter has found another biotech company to love. And he’s buying it, snatching it out of the IPO queue. The pharma giant said Tuesday morning that it will pay $1.05 billion in cash for Peloton Therapeutics, adding another $1.15 billion in milestones as they determine if the biotech’s approach to cancer is as promising as it looks.

https://www.pelotontherapeutics.com/pipeline

with his tweet!! Not bloody good enough IMHO!!

race for new-wave JK inhibitors.....https://endpts.com/pfizer-jumps-into-the-heated-phiii-race-for-new-wave-jak-inhibitors-but-safety-frets-loom-large/

Sareum poised to miss the boat if Parker doesn't pull his bloody finger out......

2200 tomorrow so Thursday promises to be interesting, or not.....

http://investor.sierraoncology.com/2019-05-08-Sierra-Oncology-Reports-First-Quarter-2019-Results

Thanks Thoth2, is the 28p in respect of SRA737 alone? What are your numbers and timescales re 1801 and 1802 notwithstanding all the current unknowns.